HCP
DGX icon

Hexagon Capital Partners’s Quest Diagnostics DGX Stock Holding History

Hexagon Capital Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46
Closed -$7.78K – 486
2025
Q1 		$7.78K Buy
46
+7
+18% +$1.15K ﹤0.01% 1046
2024
Q4 		$5.88K Buy
39
+13
+50% +$2.02K ﹤0.01% 1157
2024
Q3 		$4.04K Buy
+26
New +$3.88K ﹤0.01% 1101
2023
Q3 		– Sell
-2
Closed -$281 – 1427
2023
Q2 		$281 Sell
2
-3
-60% -$414 ﹤0.01% 1327
2023
Q1 		$707 Sell
5
-39
-89% -$5.58K ﹤0.01% 1224
2022
Q4 		$6.88K Buy
+44
New +$6.32K ﹤0.01% 831

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Hexagon Capital Partners's DGX Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Quest Diagnostics (DGX) in Q2 2025, closing a stake of 46 shares — an estimated $7.78K sold.

Hexagon Capital Partners first reported a position in DGX in Q4 2022 and held it in 6 quarters. The position peaked at $7.78K in Q1 2025. 991 funds tracked by Wall St. Rank hold DGX as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Quest Diagnostics position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 46 Quest Diagnostics shares in Q2 2025, an estimated $7.78K.
  • Hexagon Capital Partners first reported a position in Quest Diagnostics in Q4 2022 and held it in 6 quarters.
  • Hexagon Capital Partners's Quest Diagnostics position peaked at $7.78K in Q1 2025.
  • 991 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.